Orforglipron: the GLP-1 pill
A non-peptide, once-daily tablet with no food or water restrictions. It produced about 12% average weight loss in its phase 3 trial, and was approved in the USA in 2026.
CagriSema: amylin plus GLP-1
A weekly injection combining cagrilintide (an amylin analogue, another fullness hormone) with semaglutide. It produced around 20 – 23% average loss in the REDEFINE-1 trial, and has been filed for approval.
Retatrutide: the triple agonist
It acts on GIP, GLP-1 and glucagon. Glucagon may increase energy use and liver fat burning. Phase 2 showed about 24% loss at 48 weeks, and phase 3 results have been even higher. Filing is expected around 2027.
Others to watch
- Survodutide (GLP-1/glucagon): promising for fatty liver
- Amycretin (GLP-1/amylin in one molecule): injection and tablet
- MariTide: designed for monthly dosing
- Muscle-sparing add-ons such as bimagrumab: still experimental
A safety warning
Products sold online as "research peptides", including unapproved retatrutide, are not for human use. Their purity and dose are unknown. Please don't self-inject. Ask us about approved options instead.
Status as of November 2026, from public company and regulatory announcements.
This article is for general education and is not medical advice. Results vary from person to person.